Drug intelligence / Profile preview

ANG-0623

Development stage: Unknown
Lead developer: Angel Pharmaceuticals
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Administration: Oral

Overview

ANG-0623 is a third-generation, highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed by Angel Pharmaceuticals. It is designed for high brain penetration and low cerebrospinal fluid exposure, suggesting strong binding affinity to brain tissue and a low free fraction in the CNS. This pharmacokinetic profile gives ANG-0623 unique potential advantages for treating central nervous system diseases such as multiple sclerosis and primary CNS lymphomas. The drug has received IND approval in China and the US for clinical trials targeting multiple sclerosis[1][2][7].

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on ANG-0623.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANG-0623.

Explore the full profile